G 2/21: how to support inventive steps in patentability

Post-published evidence can be crucial to establishing patentability. G 2/21, the European Patent Office (EPO)’s referral to the Enlarged Board of Appeal (EBA) on the question of whether post-published evidence can be used to support the concept of “inventive step”.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

WATCH: Interview with Mythili Markowski, director at Regeneron

8 May 2026 LSIPR's senior reporter Marisa Woutersen speaks with Mythili Markowski of Regeneron on why new USPTO guidance is putting post-grant proceedings under the spotlight and how in-house teams are responding.

Europe

IP in the deal room: The risks that bite before, during and after closing

7 May 2026 Experts from Johnson & Johnson and Novartis took the stage at INTA to share the pitfalls lurking inside mergers, acquisitions and spin-offs and what in-house counsel can do about them.

Americas

Teva can pursue monopoly claims over rival’s ‘exclusive pharmacy deal’

7 May 2026 A California judge has denied Corcept’s bid to dismiss the lawsuit over its drug for a rare hormonal disorder, allowing the litigation to proceed on all core counts.

More features

WATCH: Interview with Mythili Markowski, director at Regeneron

Patent office fee increases: What applicants must know

UK patent office adopts EPO standards for AI inventions

Closing the women's health gap offers ‘benefits for all’

European patent offices raise fees

Argentina’s patent reset: Why pharma can no longer ignore Latin America's second-largest market

IndiaMart v CDSCO: A test of intermediary liability

EPO reports record patent filings, but pharma and biotech lag

G 2/21: how to support inventive steps in patentability

More on this story

Editor's picks

Editor's picks

More features